Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New RNA test could spot brain tumors without surgery

NCT ID NCT06575452

Diagnosis Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether chemical marks on RNA molecules found in blood and urine can help diagnose gliomas, a type of brain tumor. Researchers will collect samples from 228 adults scheduled for brain surgery and compare them to healthy controls. The goal is to develop a non-invasive test that could improve diagnosis and monitor tumor changes without relying solely on MRI scans.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood or urine test to diagnose gliomas and track their progression without repeated MRIs.
What could go wrong
This is an early-stage diagnostic study, not a treatment trial. The RNA markers may not prove accurate enough for clinical use, and results may not apply to all glioma types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 228 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

May 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male / female over 18 years of age, * Surgery (tumor resection) scheduled at Montpellier University Hospital for suspected, diffuse glioma, confirmed on tissue sample: IDH mutated grade 2 glioma (excluding tumors with a focus of grade 3 or 4 glioma), IDH mutated grade 3 glioma or GBM, IDH wild-type, * No history of treatment (surgery, radiotherapy or chemotherapy) for glioma, * Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures, * Patient has given express written informed consent prior to any study procedure, * Patient affiliated to a French health insurance. Exclusion Criteria: * Patients whose regular follow-up is impossible for psychological, family, social or geographical reasons, * Patients under guardianship, curatorship or safeguard of justice, * Pregnant and/or breast-feeding patient (information gathered from the medical file, as part of the patient's standard medical care and follow-up), * Histo-molecular diagnosis of grade 4 IDH-mutated astrocytoma, * For grade 2 gliomas, presence within the tumor of one or more higher-grade sites (3 or 4).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioblastoma, IDH wild-type are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

astrocytoma, IDH-mutant, grade 2 glioma IDH-mutant anaplastic astrocytoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU Montpellier - Hôpital St Eloi

    RECRUITING

    Montpellier, 34090, France

  • Insitut Régional du Cancer de Montpellier

    RECRUITING

    Montpellier, Hérault, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.